
Aerie Pharmaceuticals AERI
Quarterly report 2022-Q3
added 05-16-2026
Aerie Pharmaceuticals Interest Expense 2011-2026 | AERI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.9 M | -22.2 M | -12.2 M | -22.8 M | -1.17 M | 2.54 M | 2.49 M | 628 K | 3.8 M | 75 K | 109 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.8 M | -27.9 M | -6.96 M |
Quarterly Interest Expense Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -59 K | -1.19 M | -1.56 M | - | -7.26 M | -7.17 M | -7.71 M | - | -6.04 M | -5.63 M | -5.22 M | - | -6.08 M | -1.09 M | 111 K | - | -24 M | 663 K | 96 K | - | 597 K | 604 K | 597 K | - | 600 K | 622 K | 688 K | - | 629 K | 622 K | 617 K | - | 6.33 M | 6.33 M | 6.33 M | - | 1.48 M | 1.09 M | 293 K | - | 15 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.33 M | -24 M | -1.44 M |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
501 K | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
134 K | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
2.4 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
496 K | $ 5.77 | -1.7 % | $ 85.7 M | ||
|
Cronos Group
CRON
|
-241 K | $ 2.73 | -0.36 % | $ 1.05 B | ||
|
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
47 K | $ 34.17 | 3.55 % | $ 1.26 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | ||
|
Bausch Health Companies
BHC
|
-142 M | $ 5.4 | -1.28 % | $ 2 B | ||
|
Organogenesis Holdings
ORGO
|
-5 K | $ 2.66 | - | $ 337 M | ||
|
Pacira BioSciences
PCRX
|
-373 K | $ 24.36 | 4.33 % | $ 1.13 B | ||
|
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.05 | 0.96 % | $ 113 M | ||
|
Solid Biosciences
SLDB
|
824 K | $ 6.88 | 3.93 % | $ 602 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 1.06 | -3.64 % | $ 1.32 M | ||
|
Jupiter Wellness
JUPW
|
152 K | - | - | $ 33.6 M | ||
|
Tilray
TLRY
|
46.6 M | $ 5.45 | 3.02 % | $ 3.37 B | ||
|
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | ||
|
Evolus
EOLS
|
-539 K | $ 6.25 | 2.63 % | $ 403 M | ||
|
Sundial Growers
SNDL
|
81 K | $ 1.44 | -0.69 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
54.2 M | $ 9.13 | 8.05 % | $ 488 M | ||
|
Veru
VERU
|
768 K | $ 2.31 | -1.7 % | $ 33.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
2.78 M | $ 23.46 | 0.09 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
764 K | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
34.3 K | $ 0.76 | -0.12 % | $ 3.06 M | ||
|
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
5.15 M | $ 7.17 | 1.85 % | $ 283 M | ||
|
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
3.13 M | $ 0.68 | -6.88 % | $ 34 M | ||
|
Viatris
VTRS
|
471 M | $ 16.26 | -2.34 % | $ 18.9 B | ||
|
Zomedica Corp.
ZOM
|
-144 K | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
27 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-623 K | $ 0.76 | -4.74 % | $ 27.3 M | ||
|
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
27.3 K | $ 0.78 | 2.67 % | $ 3.35 M | ||
|
TherapeuticsMD
TXMD
|
300 K | $ 2.11 | -0.47 % | $ 24.4 M |